vs
Side-by-side financial comparison of Insulet Corporation (PODD) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $661.7M, roughly 1.2× SouthState Bank Corp). SouthState Bank Corp runs the higher net margin — 34.1% vs 13.0%, a 21.2% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs 33.2%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.
PODD vs SSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $661.7M |
| Net Profit | $101.6M | $225.8M |
| Gross Margin | 72.6% | — |
| Operating Margin | 18.7% | 15.1% |
| Net Margin | 13.0% | 34.1% |
| Revenue YoY | 31.2% | — |
| Net Profit YoY | 0.9% | 153.5% |
| EPS (diluted) | $1.42 | $2.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $661.7M | ||
| Q4 25 | $783.7M | $581.1M | ||
| Q3 25 | $706.3M | $599.7M | ||
| Q2 25 | $649.1M | $577.9M | ||
| Q1 25 | $569.0M | $544.5M | ||
| Q4 24 | $597.5M | $369.8M | ||
| Q3 24 | $543.9M | $351.5M | ||
| Q2 24 | $488.5M | $350.3M |
| Q1 26 | — | $225.8M | ||
| Q4 25 | $101.6M | $247.7M | ||
| Q3 25 | $87.6M | $246.6M | ||
| Q2 25 | $22.5M | $215.2M | ||
| Q1 25 | $35.4M | $89.1M | ||
| Q4 24 | $100.7M | $144.2M | ||
| Q3 24 | $77.5M | $143.2M | ||
| Q2 24 | $188.6M | $132.4M |
| Q1 26 | — | — | ||
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — |
| Q1 26 | — | 15.1% | ||
| Q4 25 | 18.7% | 54.3% | ||
| Q3 25 | 16.7% | 53.6% | ||
| Q2 25 | 18.7% | 48.8% | ||
| Q1 25 | 15.6% | 22.3% | ||
| Q4 24 | 18.3% | 50.7% | ||
| Q3 24 | 16.2% | 53.1% | ||
| Q2 24 | 11.2% | 49.3% |
| Q1 26 | — | 34.1% | ||
| Q4 25 | 13.0% | 42.6% | ||
| Q3 25 | 12.4% | 41.1% | ||
| Q2 25 | 3.5% | 37.2% | ||
| Q1 25 | 6.2% | 16.4% | ||
| Q4 24 | 16.9% | 39.0% | ||
| Q3 24 | 14.2% | 40.7% | ||
| Q2 24 | 38.6% | 37.8% |
| Q1 26 | — | $2.28 | ||
| Q4 25 | $1.42 | $2.47 | ||
| Q3 25 | $1.24 | $2.42 | ||
| Q2 25 | $0.32 | $2.11 | ||
| Q1 25 | $0.50 | $0.87 | ||
| Q4 24 | $1.38 | $1.88 | ||
| Q3 24 | $1.08 | $1.86 | ||
| Q2 24 | $2.59 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.9B |
| Total DebtLower is stronger | $930.8M | — |
| Stockholders' EquityBook value | $1.5B | $9.0B |
| Total Assets | $3.2B | $68.0B |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.9B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | — | ||
| Q2 25 | $939.0M | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | — | $9.0B | ||
| Q4 25 | $1.5B | $9.1B | ||
| Q3 25 | $1.4B | $9.0B | ||
| Q2 25 | $1.5B | $8.8B | ||
| Q1 25 | $1.3B | $8.6B | ||
| Q4 24 | $1.2B | $5.9B | ||
| Q3 24 | $1.1B | $5.9B | ||
| Q2 24 | $998.4M | $5.7B |
| Q1 26 | — | $68.0B | ||
| Q4 25 | $3.2B | $67.2B | ||
| Q3 25 | $3.0B | $66.0B | ||
| Q2 25 | $3.5B | $65.9B | ||
| Q1 25 | $3.5B | $65.1B | ||
| Q4 24 | $3.1B | $46.4B | ||
| Q3 24 | $3.0B | $46.1B | ||
| Q2 24 | $2.9B | $45.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.64× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | — |
| Free Cash FlowOCF − Capex | $48.2M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 17.2% | — |
| Cash ConversionOCF / Net Profit | 1.80× | — |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $183.3M | $232.1M | ||
| Q3 25 | $125.7M | $122.4M | ||
| Q2 25 | $196.5M | $72.6M | ||
| Q1 25 | $63.8M | $-126.3M | ||
| Q4 24 | $147.7M | $354.3M | ||
| Q3 24 | $98.5M | $-246.8M | ||
| Q2 24 | $96.5M | $126.8M |
| Q1 26 | — | — | ||
| Q4 25 | $48.2M | $215.5M | ||
| Q3 25 | $100.1M | $101.7M | ||
| Q2 25 | $177.9M | $52.5M | ||
| Q1 25 | $51.5M | $-139.1M | ||
| Q4 24 | $94.1M | $340.9M | ||
| Q3 24 | $71.8M | $-254.2M | ||
| Q2 24 | $74.0M | $117.3M |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 37.1% | ||
| Q3 25 | 14.2% | 17.0% | ||
| Q2 25 | 27.4% | 9.1% | ||
| Q1 25 | 9.1% | -25.5% | ||
| Q4 24 | 15.7% | 92.2% | ||
| Q3 24 | 13.2% | -72.3% | ||
| Q2 24 | 15.1% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | 17.2% | 2.9% | ||
| Q3 25 | 3.6% | 3.5% | ||
| Q2 25 | 2.9% | 3.5% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 9.0% | 3.6% | ||
| Q3 24 | 4.9% | 2.1% | ||
| Q2 24 | 4.6% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.80× | 0.94× | ||
| Q3 25 | 1.43× | 0.50× | ||
| Q2 25 | 8.73× | 0.34× | ||
| Q1 25 | 1.80× | -1.42× | ||
| Q4 24 | 1.47× | 2.46× | ||
| Q3 24 | 1.27× | -1.72× | ||
| Q2 24 | 0.51× | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
